← Leaderboards
David R. Milich
Immune Complex Corporation
$21,377,356
Attributed
$22,704,997
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,704,997 · 8
By mechanism
R01$17,254,003 · 5
R44$4,627,340 · 1
R43$823,654 · 2
Top collaborators
- Fidel P Zavala4 shared
- David C Whitacre1 shared
Most similar at Immune Complex Corporation
Same institution · by research overlap
- Ashley J Birkett$1,276,291
Others in their field
Top investigators on “Antigens”
- Barton F Haynes · Duke University$488,918,563
- Lawrence Corey · Fred Hutchinson Cancer Center$325,880,100
- Dennis R. Burton · Scripps Research Institute$291,395,948
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$245,204,950
- Jeffrey P Krischer · University Of South Florida$208,289,343
- Dan H. Barouch · Fred Hutchinson Cancer Center$124,506,327
Research focus
AntigensHybridsVaccinesCore ProteinT-LymphocyteCd4 Positive T LymphocytesAdjuvantHepatitis BInfectionIn VivoVaccine CandidateChronicPreventSiteIn VitroHepatitis B VirusWoodchuckB-LymphocytesDesignImmunogenicityLaboratory MouseLiverAntibodiesComplication
Grant awards (39)
Epitope-Based CSP Vaccines Optimized to Achieve Long-Term Sterile Immunity$688,369
R01 · FY2025 · AI · contact PI
Epitope-Based CSP Vaccines Optimized to Achieve Long-Term Sterile Immunity$688,369
R01 · FY2024 · AI · contact PI
Epitope-Based CSP Vaccines Optimized to Achieve Long-Term Sterile Immunity$688,369
R01 · FY2023 · AI · contact PI
A therapeutic vaccine for chronic hepatitis B$858,609
R44 · FY2020 · AI · contact PI
A therapeutic vaccine for chronic hepatitis B$878,409
R44 · FY2019 · AI · contact PI
An Epitope-Focused Pediatric RSV Vaccine$224,141
R43 · FY2016 · AI · contact PI
A Therapeutic Vaccine for Chronic Hepatitis B$981,428
R44 · FY2014 · AI · contact PI
A Therapeutic Vaccine for Chronic Hepatitis B$982,569
R44 · FY2013 · AI · contact PI
A Therapeutic Vaccine for Chronic Hepatitis B$926,325
R44 · FY2012 · AI · contact PI
Multiepitope circumsporozoite P.falciparum malaria subunit vaccine displayed on v$639,675
R01 · FY2012 · AI · contact PI
Mechanisms of Chronic Hepatitis B Infection and Therapeutic Vaccines$777,154
R01 · FY2011 · AI · contact PI
Multiepitope circumsporozoite P.falciparum malaria subunit vaccine displayed on v$597,424
R01 · FY2011 · AI · contact PI
A Therapeutic Vaccine for Chronic Hepatitis B$300,000
R43 · FY2011 · AI · contact PI
Mechanisms of Chronic Hepatitis B Infection and Therapeutic Vaccines$784,979
R01 · FY2010 · AI · contact PI
Multiepitope circumsporozoite P.falciparum malaria subunit vaccine displayed on v$599,338
R01 · FY2010 · AI · contact PI
A Therapeutic Vaccine for Chronic Hepatitis B$299,513
R43 · FY2010 · AI · contact PI
Mechanisms of Chronic Hepatitis B Infection and Therapeutic Vaccines$769,814
R01 · FY2009 · AI · contact PI
Multiepitope circumsporozoite P.falciparum malaria subunit vaccine displayed on v$594,705
R01 · FY2009 · AI · contact PI
Mechanisms of Chronic Hepatitis B Infection and Therapeutic Vaccines$747,395
R01 · FY2008 · AI · contact PI
DEVELOPMENT OF THE HBcAG AS A VACCINE CARRIER PLATFORM$531,825
R01 · FY2008 · AI · contact PI
Mechanisms of Chronic Hepatitis B Infection and Therapeutic Vaccines$739,678
R01 · FY2007 · AI · contact PI
DEVELOPMENT OF THE HBcAG AS A VACCINE CARRIER PLATFORM$528,945
R01 · FY2007 · AI · contact PI
DEVELOPMENT OF THE HBcAG AS A VACCINE CARRIER PLATFORM$531,567
R01 · FY2006 · AI · contact PI
Development of Preventative and Therapeutic HCV Vaccines$415,608
R01 · FY2006 · AI · contact PI
MECHANISMS OF CHRONIC HEPATITIS B INFECTION$703,710
R01 · FY2005 · AI
DEVELOPMENT OF THE HBcAG AS A VACCINE CARRIER PLATFORM$531,258
R01 · FY2005 · AI
Development of Preventative and Therapeutic HCV Vaccines$415,994
R01 · FY2005 · AI
MECHANISMS OF CHRONIC HEPATITIS B INFECTION$683,213
R01 · FY2004 · AI
DEVELOPMENT OF THE HBcAG AS A VACCINE CARRIER PLATFORM$556,773
R01 · FY2004 · AI
Development of Preventative and Therapeutic HCV Vaccines$406,659
R01 · FY2004 · AI
MECHANISMS OF CHRONIC HEPATITIS B INFECTION$663,313
R01 · FY2003 · AI
Development of Preventative and Therapeutic HCV Vaccines$222,216
R01 · FY2003 · AI
MECHANISMS OF CHRONIC HEPATITIS B INFECTION$643,993
R01 · FY2002 · AI
DEVELOPMENT OF THE HBCAG AS A VACCINE CARRIER PLATFORM$320,000
R01 · FY2002 · AI
MECHANISMS OF CHRONIC HEPATITIS B INFECTION$558,374
R01 · FY2001 · AI
DEVELOPMENT OF THE HBCAG AS A VACCINE CARRIER PLATFORM$320,000
R01 · FY2001 · AI
DEVELOPMENT OF THE HBCAG AS A VACCINE CARRIER PLATFORM$306,400
R01 · FY2000 · AI
MECHANISMS OF CHRONIC HEPATITIS B INFECTION$305,427
R01 · FY2000 · AI
MECHANISMS OF CHRONIC HEPATITIS B INFECTION$293,459
R01 · FY2000 · AI